Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis

Launched by CAIRO UNIVERSITY · Feb 23, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called nifuroxazide to see how well it works and how safe it is for treating hepatic encephalopathy in patients with liver cirrhosis. Hepatic encephalopathy is a condition that affects the brain and can happen when the liver is not functioning properly. The trial is specifically looking at patients who have moderate to severe symptoms, known as grade II or III hepatic encephalopathy.

To be eligible for this study, patients must be at least 18 years old, have a history of liver disease, and show signs of hepatic encephalopathy confirmed by tests indicating high ammonia levels. However, patients with certain conditions, such as serious neurological issues, recent use of specific medications, or significant kidney problems, will not be included in the trial. If you or someone you know is eligible and chooses to participate, they will receive the medication and be monitored closely for any changes in their condition. The trial is currently recruiting participants, and all genders are welcome to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients suffering from liver cirrhosis aging above 18 years who will be admitted to hospital with neuropsychiatric condition suggestive of hepatic encephalopathy (grade II or III) confirmed by their known previous hepatic disease by history, clinical examination and laboratory investigations in the form of hyperammonemia with Model for End-Stage Liver Disease (MELD) score ≤ 25 and patients are able to swallow.
• Exclusion Criteria:
• • Patients with neurological or communication problems.
• • Degenerative central nervous system (CNS) disease.
• • Any significant psychiatric illness.
• • Patients with previous intake of nifuroxazide and rifaximin within the last month.
• • Presence of underlying renal impairment (serum creatinine ≥ 2 mg/dL).
• • Alcohol consumption within prior 4 weeks.
• • Non-hepatic metabolic encephalopathy.
• • Anemia with hemoglobin level \< 7 g/dL.